2022
COMBINED LOCAL TREATMENT OF BRAIN METASTASES: SURGERY AND POSTOPERATIVE STEREOTACTIC RADIOTHERAPY
FADRUS, Pavel, Václav VYBÍHAL, Vilém JURÁŇ, Ivana ROŠKOVÁ, Andrea ŠPRLÁKOVÁ-PUKOVÁ et. al.Základní údaje
Originální název
COMBINED LOCAL TREATMENT OF BRAIN METASTASES: SURGERY AND POSTOPERATIVE STEREOTACTIC RADIOTHERAPY
Autoři
FADRUS, Pavel (203 Česká republika), Václav VYBÍHAL (203 Česká republika), Vilém JURÁŇ (203 Česká republika), Ivana ROŠKOVÁ (703 Slovensko), Andrea ŠPRLÁKOVÁ-PUKOVÁ (203 Česká republika), Tereza KOPŘIVOVÁ (203 Česká republika), Miloš KEŘKOVSKÝ (203 Česká republika), Radek LAKOMÝ (203 Česká republika), Tomáš KAZDA (203 Česká republika), Ludmila HYNKOVÁ (203 Česká republika), Renata BELANOVÁ (203 Česká republika, domácí), Marek VEČEŘA (703 Slovensko, domácí), Markéta HERMANOVÁ (203 Česká republika), Radim JANČÁLEK (203 Česká republika), Jiří ŠÁNA (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí), Pavel ŠLAMPA (203 Česká republika) a Martin SMRČKA (203 Česká republika)
Vydání
27th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), 2022
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30204 Oncology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Organizační jednotka
Středoevropský technologický institut
UT WoS
000888571001288
Klíčová slova anglicky
BRAIN METASTASES; COMBINED LOCAL TREATMENT
Příznaky
Mezinárodní význam
Změněno: 31. 7. 2024 13:47, Mgr. Tereza Miškechová
Anotace
V originále
INTRODUCTION: Modern comprehensive local treatment of BM provides the possibility of adequate local control while maintaining a satisfactory quality of life. METHODS: Patients after metastasectomy and postoperative radiotherapy treated between 2007-2020 were evaluated. Local control was assessed separately at the site of the operated MM (localPFS) and separately in other parts of the brain (distalPFS). RESULTS: A total of 118 patients were enrolled (70 with WBRT), 54% were women, the median age was 60 years, the median performance status Karnofsky 80%. The most common primary tumor was lung carcinoma (39/118, 33%). Targeted stereotactic radiotherapy was significantly more often indicated in operations performed after 2016 (p < 0.001). In the period 2013-2019, gross total resection was achieved significantly more often (83 vs 64%; p = 0.061). The median follow-up is 49 months. The median overall survival (OS) is 9 months (6.2 - 12), the median localPFS 22 months (14 - unattainable), median distPFS 11 months (6.8 - 27 months), median extracranialPFS 11 months (5.9 - 15). Stratification of patients according to the prognostic index brainmetgpa.com led to significant separation of patients for OS (p = 0.00017). In a multivariate analysis, stereotactic radiotherapy was statistically significant positive prognostic factor for OS compared to WBRT (median OS 17 vs. 5.6 months, HR 0.59, p = 0.018) with no effect on localPFS. CONCLUSION: Our results of comprehensive local treatment of BM are comparable with the results presented by important foreign studies from prestigious oncology centers. We described targeted stereotactic postoperative radiotherapy as an independent positive prognostic factor after brain metastasectomy.
Návaznosti
| NV18-03-00398, projekt VaV |
| ||
| NV19-03-00501, projekt VaV |
| ||
| NV19-03-00559, projekt VaV |
|